CF PharmTech, Inc. (HKG:2652)
Hong Kong
· Delayed Price · Currency is HKD 29.50
-4.56 (-13.39%)
At close: Mar 9, 2026
CF PharmTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 603.93 | 607.75 | 556.42 | 349.13 | 41.99 | 4.86 |
| Revenue Growth (YoY) | 1338.42% | 9.22% | 59.38% | 731.54% | 764.11% | - |
| Cost of Revenue | 121.03 | 117.67 | 101.85 | 83.46 | 21.78 | 4.3 |
| Gross Profit | 482.9 | 490.09 | 454.57 | 265.67 | 20.2 | 0.56 |
| Selling, General & Admin | 349.35 | 363.37 | 319.93 | 243.81 | 138.88 | 222.2 |
| Research & Development | 121.8 | 121.85 | 132.79 | 107.23 | 98.46 | 201.32 |
| Other Operating Expenses | - | - | - | - | 0.77 | 0.47 |
| Operating Expenses | 473.4 | 486.51 | 452.4 | 351.45 | 238.1 | 423.99 |
| Operating Income | 9.5 | 3.58 | 2.17 | -85.78 | -217.9 | -423.43 |
| Interest Expense | -2.16 | -1.78 | -0.17 | -0.16 | -0.14 | - |
| Interest & Investment Income | 0.42 | 0.61 | 3.92 | 4.29 | 20.71 | 16.03 |
| Earnings From Equity Investments | -0.06 | -0.07 | -0.1 | - | - | - |
| Currency Exchange Gain (Loss) | - | - | -0.2 | 2.5 | -1.76 | -4.64 |
| Other Non Operating Income (Expenses) | 17.73 | 16.85 | 16.82 | 8.54 | -0.08 | -0.18 |
| EBT Excluding Unusual Items | 25.42 | 19.18 | 22.44 | -70.62 | -199.18 | -412.22 |
| Gain (Loss) on Sale of Investments | -0.27 | - | - | - | 0.44 | 3.05 |
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 | 0.01 |
| Asset Writedown | - | - | - | - | -0.02 | -0.1 |
| Other Unusual Items | - | - | - | - | 4.57 | 4.13 |
| Pretax Income | 25.15 | 19.18 | 22.44 | -70.62 | -194.2 | -405.13 |
| Income Tax Expense | -2.6 | -1.9 | -9.28 | -21.22 | -62.47 | - |
| Net Income | 27.75 | 21.09 | 31.73 | -49.4 | -131.73 | -405.13 |
| Net Income to Common | 27.75 | 21.09 | 31.73 | -49.4 | -131.73 | -405.13 |
| Net Income Growth | - | -33.53% | - | - | - | - |
| Shares Outstanding (Basic) | 371 | 371 | 371 | 371 | - | - |
| Shares Outstanding (Diluted) | 371 | 371 | 371 | 371 | - | - |
| EPS (Basic) | 0.07 | 0.06 | 0.09 | -0.13 | - | - |
| EPS (Diluted) | 0.07 | 0.06 | 0.09 | -0.13 | - | - |
| EPS Growth | - | -33.53% | - | - | - | - |
| Free Cash Flow | -61.67 | -71.2 | 1.65 | -45.72 | -247.95 | -287.05 |
| Free Cash Flow Per Share | -0.17 | -0.19 | 0.00 | -0.12 | - | - |
| Gross Margin | 79.96% | 80.64% | 81.69% | 76.09% | 48.12% | 11.48% |
| Operating Margin | 1.57% | 0.59% | 0.39% | -24.57% | -518.98% | -8714.78% |
| Profit Margin | 4.59% | 3.47% | 5.70% | -14.15% | -313.74% | -8337.95% |
| Free Cash Flow Margin | -10.21% | -11.72% | 0.30% | -13.10% | -590.55% | -5907.83% |
| EBITDA | 65.62 | 57.27 | 50.53 | -51.53 | -191.71 | -408.6 |
| EBITDA Margin | 10.87% | 9.42% | 9.08% | -14.76% | - | - |
| D&A For EBITDA | 56.12 | 53.69 | 48.37 | 34.25 | 26.19 | 14.83 |
| EBIT | 9.5 | 3.58 | 2.17 | -85.78 | -217.9 | -423.43 |
| EBIT Margin | 1.57% | 0.59% | 0.39% | -24.57% | - | - |
| Advertising Expenses | - | 181.7 | 165.59 | 93.59 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.